Effects of antisense oligonucleotides targeting VEGF on radio sensitivity of uterine cervix cancer Hela cells

2009 ◽  
Vol 8 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Li’na Xing ◽  
Li Qi
2020 ◽  
Author(s):  
XiaXia Man ◽  
XiaoLin Yang ◽  
ZhenTong Wei ◽  
YuYing Tan ◽  
WanYing Li ◽  
...  

Abstract Background It has previously accepted that several types of human cancer constitutively express CXCL1, which may implicated in various aspects of tumors. Here, we sought to assess the expression and of CXCL1 in human uterine cervix cancer (UCC) and its potential role and mechanism in UCC. Methods CXCL1 protein expression in a uterine cervical tissue microarray was assessed by immunohistochemistry. The roles of CXCL1 on HeLa UCC cells were detected by CCK-8, transwell and apoptosis assays. Western blotting and ERK1/2 blocker PD98059 were utilized to explore whether ERK signal was implicated in CXCL1-mediated UCC processes. Results CXCL1 was expressed by HeLa, PHM1-41 cells as well as cervical tissues, in which UCC tissues showed an obviously high level of CXCL1 compared with non-cancerous tissues. Additionally, of the cancer tissues, CXCL1 high-level expression was notably relevant to poor clinical stages. In vitro, the growth and migration of HeLa cells were enhanced in the presence of exogenous CXCL1. Gain-function assays revealed that CXCL1 overexpression promoted growth and migration response to HeLa cells via autocrine/paracrine manners. Moreover, CXCL1 also led to the inhibition of apoptosis in HeLa cells. Finally, CXCL1 overexpression in HeLa cells influenced the expression of ERK signal-related genes including ERK, p-ERK, cyclin D1 and Bax, and cell malignant behaviors derived from CXCL1 overexpresion were further interrupt in the presence of PD98059. Conclusion Our findings provided the potential roles of CXCL1 as a promoter and the novel understanding of the functional relation of CXCL1 with ERK signal pathway in UCC.


1987 ◽  
Vol 23 (6) ◽  
pp. 1038
Author(s):  
J U Chung ◽  
B I Choi ◽  
S H Kim ◽  
M C Han ◽  
C W Kim

2004 ◽  
Vol 93 (1) ◽  
pp. 182-188 ◽  
Author(s):  
Emmanuel Contassot ◽  
Mirna Tenan ◽  
Valérie Schnüriger ◽  
Marie-Françoise Pelte ◽  
Pierre-Yves Dietrich

2002 ◽  
Vol 12 (6) ◽  
pp. 773-776 ◽  
Author(s):  
C. R. R. Miranda ◽  
C. N. De Resende ◽  
C. F. E. Melo ◽  
A. L. Costa ◽  
H. Friedman

Depression in cancer patients is common and may affect treatment outcome either directly (by lowering defenses) or indirectly (by lowering compliance). Neoadjuvant chemotherapy for advanced uterine cervix or breast cancer is a strenuous undertaking and may lead to depression and impair patients' willingness to comply with the rest of the treatment (eg, surgery or radiotherapy).We compare Beck Depression Inventory (BDI) scores both before and after neoadjuvant chemotherapy in order to verify if depression influences treatment outcome. We studied 22 advanced uterine cervix and 20 breast cancer patients submitted to three courses of neoadjuvant chemotherapy. We used cisplatin and ifosfamide for cervix, and fluorouracil, adriamycin, and cyclophosphamide for breast cancer. We did not identify significant differences in the number of depressed patients, before and after treatment. Cognitive affective, somatic-performance, and total BDI scores were not significantly different from before to after chemotherapy for both breast and uterine cervix cancer. After treatment, the number of depressive breast cancer patients increased while the number of uterine cervix cancer patients decreased. This trend to depression was found more often in less responsive breast cancer patients than in the more responsive cervix cancer patients. We were not able to link depression to treatment failure or success, but patients who responded to treatment were less depressed at the end of treatment.


Sign in / Sign up

Export Citation Format

Share Document